Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose rifampicin safety trial in pulmonary tuberculosis
NL-OMON59904Phase 3Suspended
- Sponsor
- IRCCS Ospedale Sacro Cuore Don Calabria
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rifampicin in Tuberculosis (TB) and pulmonary tuberculosis (TB) (2 arms), sponsored by IRCCS Ospedale Sacro Cuore Don Calabria. Primary endpoint: Incidence of hepatotoxicity. Started Jan 2024; status: suspended.
02
Drugs
rifampicin
03
Conditions
Tuberculosis (TB)pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NL-OMON59904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59904.